Portosystemic encephalopathy (PSE) is a major complication of trans-jugular intrahepatic porto-systemic shunt (TIPS) placement. Most devices are self-expandable polytetrafluoroethylene-covered stent grafts (PTFE-SGs) that are dilated to their nominal diameter (8 or 10 mm). We investigated whether PTFE-SGs dilated to a smaller caliber (under-dilated TIPS) reduce PSE yet maintain clinical and hemodynamic efficacy. We also studied whether underdilated TIPS self-expand to nominal diameter over time.
T he transjugular intrahepatic portosystemic shunt (TIPS) is an invasive treatment of portal hypertensive bleeding, refractory ascites (RA), and vascular diseases of the liver, which improves survival. [1] [2] [3] [4] [5] The availability of self-expandable polytetrafluoroethylenecovered stent grafts (PTFE-SGs) has dramatically improved the long-term patency of TIPS.
1,2 However, its major drawback is portosystemic encephalopathy (PSE), reported in 23%-55% within the first year. [3] [4] [5] [6] [7] [8] [9] [10] [11] Current guidelines recommend that post-TIPS portocaval pressure gradient (PCG) should be reduced below 12 mm Hg, particularly for rebleeding prevention.
1,2 A PCG reduction of more than 50% has been suggested as an alternative target. 1 TIPS diameter influences PCG reduction and the eventual appearance of PSE because of a greater amount of portal blood diverted to the systemic circulation and a reduction in residual liver perfusion. [10] [11] [12] It is conceivable that balloon dilation of TIPS to diameters smaller than those currently indicated (ie, 7 mm) result in a lower risk of PSE. 12, 13 However, this undersizing is not considered permanent because PTFE-SGs are expected to expand to their nominal diameter (ie, inner maximal diameter of a fully expanded PTFE-SG). 13, 14 We hypothesized that, within the cirrhotic parenchyma, underdilated PTFE-SGs would not self-expand to nominal diameter and could reduce post-TIPS encephalopathy. Thus, the aims of this study were to determine whether underdilated TIPS reduce the incidence of PSE while maintaining clinical efficacy, and to determine whether under-dilated TIPS maintain their size with time.
Materials and Methods

Study Design and Patients
Clinical study. This part of the study was a prospective, nonrandomized 15 analysis of clinical outcomes in consecutive patients with cirrhosis scheduled for TIPS placement at the referral centers of Modena and Florence, who agreed to participate in the study. In a first set of patients PTFE-SGs ballooned to 7 mm were studied to evaluate the feasibility and safety of underdilation. Patients enrolled thereafter had PTFE-SGs underdilated to 6 mm. The latter (training group, TG) was compared with a control group (CG) including patients who had standard TIPS placed before the initiation of the study, patients who refused underdilated TIPS, and those of the TG in whom TIPS was dilated to 8 mm for technical reasons ( Figure 1A ). After completion of this initial study, dilation to 6 mm became the standard and all patients were included in a validation group (VG) to confirm TG results ( Figure 1A ). Table 1 shows inclusion and exclusion criteria. All patients were followed in a dedicated outpatient clinic for 6 months, and then in a general hepatology clinic unless TIPS dysfunction or other complications, including PSE, were observed. Doppler ultrasonography of TIPS was performed 2 weeks and 3 months after TIPS placement and every 6 months thereafter. 2 No patients received pharmacologic prophylaxis for PSE after TIPS.
Outcomes evaluated were (1) incidence of at least 1 episode of PSE grade 2 or higher as evaluated by 2 observers at follow-up 8, 9, 16 ; (2) incidence of recurrent variceal hemorrhage (VH) or ascites, defined as the need for at least 1 large-volume paracentesis (LVP) beyond 4 weeks after TIPS; (3) incidence of shunt dysfunction requiring TIPS recanalization; and (4) reduction in PCG. TIPS would be revised in case of recurrent VH, continued need for LVP, and/or if flow reversal in the intrahepatic portal branches was observed on Doppler ultrasonography.
2 PTFE-SGs (Viatorr, Gore, Flagstaff, AZ) were placed as previously described 4, 5, 7, 8 using semicompliant balloon catheters (FoxCross, Abbott Park, IL).
In the CG, the intraparenchymal tract was initially dilated to 8 mm. Patients with post-TIPS PCG !12 mm Hg had further dilation to 9 or 10 mm, unless post-TIPS PCG was at or near the hemodynamic target and/or the patient was considered with limited functional reserve of the liver. 2, 17 In the TG and VG, the intraparenchymal tract was predilated to 6 mm, and the PTCE-SG was dilated to 7 or 6 mm unless the final TIPS path was angled. During dilation of the intraparenchymal tract, balloon pressure was kept at the nominal value for 15-30 seconds, even in the lack of a complete flattening of notches at the level of portal (PVW) and hepatic vein (HVW) walls.
Immediately after TIPS placement, pressures in the portal vein, along the intraparenchymal tract of TIPS, and in the inferior vena cava were recorded until a stable tracing was obtained in each position (45-60 seconds). Permanent tracings were obtained with PowerLab (ADInstruments, Inc, Colorado Springs, CO). Post-TIPS PCG was calculated by subtracting the inferior vena cava pressure from the portal vein pressure. All procedures were performed by F.S., F.V., C.C., S.C., and M.D.S. under monitored anesthesia, without intubation and using midazolam and fentanyl as sedative and analgesic, respectively. 2, 17 Comparisons were made between patients who had the TIPS dilated to 7 mm (underdilated TIPS) versus those with diameters !8 mm (standard TIPS).
Imaging study
Patients with cirrhosis from 8 Italian referral centers (including those participating in the clinical study) who had TIPS placed using PTFE-SGs in the study period and who had an abdominal computed tomography (CT) scan Table 1 shows inclusion and exclusion criteria. The PTFE-SG inner diameter was measured at 4 sites: (1) where the PTFE-SG traverses the PVW and (2) the HVW; (3) at an intraparenchymal site equidistant from PVW and HVW; and (4) at a site close to the proximal end, just before the PTFE-SG exit into inferior vena cava. The average of the largest diameters at each of the 4 sites was calculated in the entire population grouped on the basis of both the PTFE-SG nominal diameters and the dilation diameters (Supplementary Figure 2) . To determine whether PTFE-SG self-expansion occurred, the average value of the maximal diameter at the 2 sites considered hemodynamically critical (ie, PVW and HVW, Supplementary  Figure 2 and data not shown) was plotted for each patient against time from TIPS placement. It was considered that a PTFE-SG was stable over time if its follow-up inner diameter was within AE 0.5 mm of dilation diameter.
The study protocols conformed to the ethical guidelines of the 1975 Declaration of Helsinki. The institutional review board gave approval to collect prospective and retrospective clinical, hemodynamic, and CT data. The need for informed consent was waived for patients no longer being followed at the time of data collection.
Statistical Analysis
Results are expressed as mean AE standard deviation (or standard error if specified) or percentage. Comparisons of continuous data and proportions were performed by the Student t test and the chi-square test, respectively. Either Spearman rank-order or Person correlation were run to determine relationship between continuous variables. The Kaplan-Meier method was used to estimate time-related events. Patients were censored at first episode of post-TIPS PSE, first LVP after TIPS, orthotopic liver transplantation or death or last available follow-up. Differences in observed probability were assessed using the log-rank test. Post hoc competing risks analyses were also performed using Gray test, with death and orthotopic liver transplantation as competing events. A Fine and Gray competing risks proportional hazards model was used to identify risk factors for PSE in the pooled groups. Post-TIPS death/orthotopic liver transplantation were treated as the competing events. Age, sex (female vs male), pre-TIPS model for end-stage liver disease (MELD) score, TIPS indications (ascites vs rebleeding prevention), pre-TIPS PSE, PTFE-SG dilation (6 mm vs above 6 mm), and either post-TIPS PCG <10 mm Hg or post-TIPS decrease more than 50% were incorporated in 2 alternative models. Proportional hazards assumption of the Fine and Gray models was checked by means of graphical assessment of weighted Schoenfeld-type residuals. Finally, a propensity score analysis was performed (further details in Supplementary 
Results
Clinical Study
Between November 2009 and December 2012, a total of 117 patients had a TIPS placed, of whom 95 were included in this part of the study ( Figure 1A ). Indications for TIPS were RA in 58 (61%) patients and prevention of recurrent VH in 37 (39%) patients. In the latter group, TIPS was performed within 6 weeks of the index hemorrhage in most patients ( Table 2 ). Mean follow-up for the whole cohort was 326 days. No patient was lost to CT, computed tomography; MRI, magnetic resonance imaging; PSE, portosystemic encephalopathy; PTFE-SG, polytetrafluoroethylene-covered stent graft; RA, refractory ascites; TIPS, transjugular intrahepatic portosystemic shunt; US, ultrasound; VH, variceal hemorrhage.
follow-up. Patient allocation to the different groups and clinical characteristics before and after TIPS are reported in Figure 1A and Table 2 . Clinical outcomes. The initial comparison was made between 42 patients with a PTFE-SG dilated to 7 or 6 mm (TG) and 53 patients with dilation !8 mm (CG). Patients in both groups were comparable, except that in the underdilated group RA tended to be a more frequent indication and pre-TIPS PCG was lower. No patients in either group had acute shunt occlusion. Among the 5 patients (2 in TG and 3 in CG) who underwent PCG reassessment because they still required LVP 12 weeks after TIPS placement, none required TIPS dilation (ie, PCG <12 mm Hg) and none needed further LVP 6 months after TIPS placement (Table 2) . Two patients in the CG underwent TIPS reduction for persistent PSE and heart failure, respectively.
There were no cases of recurrent VH in the 37 patients in whom TIPS was placed to prevent bleeding, including those (8 out of 12) with underdilated TIPS in whom PCG did not decrease <12 mm Hg. Among the 58 patients with RA, 13 (22.4%) required at least 1 LVP during a mean follow-up of 317 days. The probability of remaining free of LVP was 74.6% (95% confidence interval [CI], 57.6.1-91.6) and 78.6% (95% CI, 62.6-94.6; P ¼ .728; Gray test, P ¼ .923) in the TG and CG, respectively ( Figure 2A ). During follow-up at least 1 episode of PSE occurred in 39 out of 95 patients (41%). The 1-year cumulative probability of remaining free of PSE was significantly greater in TG (73.1%; 95% CI, 59.2%-87.1%) than in CG (46.0%; 95% CI, 32.2%-59.8%; P ¼ .015; Gray test, P ¼ .026) ( Figure 2B ).
Post-TIPS MELD score at different time points was significantly lower in TG than in CG (Table 2) .
Hemodynamic effects. In the 95 patients the mean post-TIPS decrease of PCG was À53 AE 15% (range, À22% to À93%). Post-TIPS PCG was significantly greater and the percent decrease in PCG lower in the underdilated group (Table 2) . Moreover, TIPS dilation (ie, 6, 7, 8, 9, and 10 mm) inversely correlated with final PCG and directly with its percent change (r s ¼ À0.285, P ¼ .001 and r s ¼ 0.380, P ¼ .0003, respectively). Post-TIPS PCG <12 mm Hg 1,4,5,11,18 tended to be reached less frequently in the underdilated group, whereas PCG values <10 mm Hg, a threshold that has been associated with increased risk of PSE, 6, 11 were significantly less frequent than in the standard TIPS group (Table 2) .
Validation group. We separately analyzed 59 patients with TIPS placed in the same centers after completion of the initial study ( Figure 1A) . No significant differences in clinical, endoscopic, and hemodynamic baseline features were found between this 6-mm dilated VG and the TG ( (Figure 2A and B) . Post-TIPS hemodynamic parameters and MELD score were also similar (Supplementary Table 1 ).
Risk factors for post-transjugular intrahepatic portosystemic shunt portosystemic encephalopathy. Table 3 shows the competing risk models to identify independent predictors of post-TIPS PSE. There were 49 events (PSE) and 9 competing events (death/liver transplant). Age, female sex, pre-TIPS PSE, PTFE-SG dilatation >6 mm, and post-TIPS PCG <10 mm Hg were independently associated with 1-year post-TIPS PSE. No evidence of lack of proportional hazards was found (data not shown). Supplementary Table 2 shows the multivariate models after removing patients with pre-TIPS PSE. Propensity score adjusted multivariate analyses showed PTFE-SG dilatation >6 mm and either post-TIPS PCG <10 mm Hg or post-TIPS PCG decrease more than 50% independently associated with 1-year post-TIPS PSE (Supplementary Table 3 ).
Supplementary Table 4 shows the comparison of main characteristics of pooled groups stratified according to PTFE-SG dilation. Supplementary Figure 3 shows the cumulative risk of PSE in patients grouped according to categorical variables and the best cutoff for age (ie, 55 years) selected after receiver operating characteristic curve analysis (data not shown). Supplementary Figure 4 shows bilirubin time course in patients stratified according to PTFE-SG dilation. Supplementary Figure 5 shows cumulative probability of remaining free of PSE Seven patients of the TG were added to the CG because of PTFE-SG dilatation to 8 mm (Supplementary Figure 1) . No difference in the comparisons of CG versus TG was observed after removing these patients from the analysis. b Mean AE standard deviation. c Five, 1, and 3 patients in CG, TG, and VG, respectively, have been referred for TIPS after 6 weeks from index bleeding. d TG versus CG, P < .05. e VG versus CG, P < .05. f Among the 17 patients with a PCG !12 mm Hg, 5 had an 8-mm PTFE-SG, 2 were dilated to 10 mm, 10 had a too advanced liver disease and/or a PCG very close to the target. g PCG re-evaluation performed in the 7 patients (3, 2, and 2 in CG, TG, and VG, respectively) needing paracentesis 12 weeks after TIPS showed a PCG <12 mm Hg (none of them needed LVP 6 months after TIPS). In the remaining 12 patients, PCG re-evaluation was performed for suspicions of TIPS dysfunction at follow-up US, but none of them showed significant increase of PCG in comparison with immediate post-TIPS values. h A total of 17/37 patients who had varices pre-TIPS had a post-TIPS endoscopy. in the subgroup of patients (n ¼ 24) with characteristics similar to those of patients enrolled in the study by Bureau et al 5 (ie, ascites as an indication, pre-TIPS MELD score below or equal to 12, no history of pre-TIPS PSE, and post-TPS PCG <12 mm Hg).
Imaging Study
A total of 226 CT scans were evaluated in this part of the study ( Figure 1B) . The mean time between PTFE-SG placement and CT scan was 252 days (median, 286; range, 1-1440 days). Supplementary Figure 2 shows average maximal diameter (ie, the largest cross-sectional inner diameter) at each of the 4 sites. PVW and HVW had the smallest diameter in underdilated PTFE-SGs, indicating that these are the hemodynamically relevant sites along the TIPS (data not shown). Therefore, diameters at these 2 sites were used to analyze stability of TIPS diameter over time in individual patients ( Figure 3) and to create the groups at risk of PSE ( Figure 2C and D) .
Of the 8-mm PTFE-SG placed, none but one of those dilated to 6 or 7 mm self-expanded and none of those dilated to nominal diameter (8 mm) maintained this diameter (they were all under 7.5 mm at follow-up) ( Figure 3A-C) .
Of the 10 mm PTFE-SG placed, 74% of those balloons dilated to 6 mm underwent self-expansion to 7 (67%) or 8 mm (7%) but none to nominal diameter ( Figure 3A) . Of those dilated to 7 mm, self-expansion occurred in 32% (all to 8 mm, none to nominal diameter) ( Figure 3B ). Of those dilated to 8 mm, self-expansion occurred in 20% (all of them to 9 mm, none to nominal diameter) ( Figure 3C ). Of those dilated to 9 mm, none selfexpanded ( Figure 3D ) and of those dilated to 10 mm none maintained nominal diameter ( Figure 3E) .
A follow-up PTFE-SG diameter of 6 mm (AE 0.5 mm) at PVW and/or HVW on CTs performed within 1 year after TIPS placement on 79 patients included in the clinical study (Supplementary Table 5 ) was associated with a significantly lower incidence of PSE ( Figure 2D ) without differences in the recurrence of ascites ( Figure 2C ).
Discussion
This is the first published study demonstrating the feasibility of underdilating PTFE-SGs at diameters as low as 6 mm and indicating that this strategy is associated with a significant decrease in the incidence of post-TIPS PSE. Importantly, the lower burden of PSE was accompanied by unchanged clinical efficacy in patients with both VH and RA.
The incidence of post-TIPS PSE was inversely related to the diameter of PTFE-SG deployment, and to post-TIPS PCG. Accordingly, the percentage of patients with post-TIPS PCG <10 mm Hg, the threshold identified as predictive of post-TIPS PSE, 6, 11 was significantly lower in the underdilated group. Therefore, dilation to 6 mm may be proposed as the initial option for TIPS placement, in particular in patients with risk factors for post-TIPS PSE. 2, 10 These results, if confirmed in randomized trials, have the potential to change clinical practice.
Several studies have compared clinical efficacy, incidence of PSE, and hemodynamics after TIPS with different diameters, with divergent results. In 2 studies (1 early interrupted randomized 8 and 1 retrospective 18 ) comparing 10 mm versus 8 mm PTFE-SG dilated to nominal diameters, patients with 8 mm PTFE-SG had similar PSE rates but lower clinical efficacy (mostly recurrence of ascites). Notably, the mean post-TIPS PCG was <10 mm Hg in both groups, making it hard to reconcile their results on clinical efficacy. Moreover, in the study by Miraglia et al, 18 50% of patients undergoing TIPS revision during follow-up for failure to control ascites had a PCG already below the target of 12 mm Hg. 1, 2, 5, 11, 17 However, a recent large randomized study reported that 8 mm PFTE-SG had similar efficacy in preventing VH compared with 10 mm, while decreasing post-TIPS PSE independent of post-TIPS PCG. 9 Our results are in agreement with previous studies showing a close correlation between post-TIPS PCG and the incidence of PSE. 6, 11 However, finding that both post-TIPS PCG <10 mm Hg and PTFE-SG dilation to 6 mm are independent predictors of PSE indicates that underdilated TIPS may protect from PSE by mechanisms other than PCG, probably by preserving liver function. The similar efficacy of underdilated and standard TIPS on VH and RA recurrence is even more complex to explain. At least 50% of patients receiving underdilated PTFE-SG had a PCG <12 mm Hg after placement. In the remaining patients it is conceivable that a partial but substantial hemodynamic response may have been sufficient to prevent rebleeding, 9, 19 similar to patients on pharmacologic prophylaxis of rebleeding. 20 However, our results on bleeding recurrence cannot be generalized to the setting of early TIPS 4 and continuous bleeding or early rebleeding.
1,2 Some patients with RA may also benefit from a partial hemodynamic response and others may benefit from further decrease in PCG because of a self-expansion albeit limited, of PTFE-SG with time. However, the fact that some patients required LVP 12 weeks after TIPS positioning despite a reassessed PCG <12 mm Hg indicates the need to further investigate the multifactorial nature of post-TIPS RA. 1, 2, 18, 21, 22 PTFE-SGs are believed to self-expand to nominal diameter even when not fully balloon-dilated at the time of TIPS placement, but the fate of PTFE-SG underdilation to less than 8 mm in the setting of a cirrhotic liver had not been previously explored. 13, 14 Herein we showed that underdilated PTFE-SGs do not self-expand to nominal diameter, and rarely expand beyond 1 mm of the dilation diameter at the hemodynamically relevant sites HVW and PVW. Of note, deployment to 6 mm of an 8 mm PTFE-SG seems to be more stable over time compared with 10 mm PTFE-SG. If our results are confirmed, dilating to 6 mm (or using PTFE-SG with nominal diameter <8 mm) may be the recommended strategy, especially in patients with RA and in those with more compromised liver function.
A clear limitation of our study is the lack of randomization. Nevertheless, groups were comparable at baseline for most clinical parameters, including factors predictive of post-TIPS encephalopathy. A higher number of patients with RA was included in the underdilated TG, and pre-TIPS PCG was lower in the same group, likely reflecting decreased circulating blood volume secondary to diuretic use and heart dysfunction. However, the VG, which confirmed the results obtained in the TG, was very similar to the CG in terms of indications and pre-TIPS PCG.
In conclusion, the present study shows that TIPS placement using PTFE-SGs underdilated to 6 mm is associated with a lower rate of encephalopathy and with the same clinical efficacy compared with PTFE-SG TIPS dilated to standard diameters. These results require confirmation in randomized trials.
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Note: To access the supplementary material accompanying this article, visit the online version of Clinical Gastroenterology and Hepatology at www.cghjournal.org, and at https://doi.org/10.1016/j.cgh.2018.01.029. Supplementary Figure 2 . Average maximal inner diameter of PTFE-SGs at each standard site after CT images processing (A and B: 8 mm and 10 mm nominal diameter PTFE-SGs, respectively). Bars represent mean AE standard error of different dilatation groups. In C an example case of implanted PTFE-SG showing a narrowing of its lumen at the level of PVW and HVW. The effects of these strictures on blood pressure curve along the PTFE-SG length are also shown (double-headed dashed-arrow indicates pressure values recorded along the intraparenchymal tract). Interobserver agreement regarding measurement of the inner diameter at each site of PTFE-SGs was excellent, as indicated by a coefficient for agreement of .96 (95% CI, 0.9-1.0). IVC, inferior vena cava; IP, intraparenchymal tract; PRX, proximal outflow; PV, portal vein. 
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